Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes

AIM: Rabeprazole is metabolized to some extent by CYP2C19. The purpose of this study was to elucidate the pharmacokinetics of each rabeprazole enantiomer in three different CYP2C19 genotype groups. METHODS: Twenty-four healthy subjects, of whom each each were homozygous extensive metabolizers (homEM...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Miura, Masatomo, Kagaya, Hideaki, Tada, Hitoshi, Uno, Tsukasa, Yasui-Furukori, Norio, Tateishi, Tomonori, Suzuki, Toshio
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Science Inc 2006
Matèries:
Pharmacogenetics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC1885016/
https://ncbi.nlm.nih.gov/pubmed/16487225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2005.02566.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars